|
| |
| | Graft Versus Host Disease - Pathophysiology & Management |
 | | The major side effects were skin breakdown and ulceration leading to discontinuation of therapy in 18% of the patients. | | | A randomized trial of thalidomide versus placebo added to cyclosporin and prednisone therapy is currently being investigated in patients with high-risk cGvHD. | | | Tacrolimus provides an effective alternative in patients with GvHD unresponsive to cyclosporin therapy. |
|
http://www.dcmsonline.org/jax-medicine/2000journals/nov2000/graft.htm
(3158 words)
|
|
| |
| | Chapter 9 |
| | The "graft" is the donated bone marrow and the "host" is the BMT patient or bone marrow recipient. | | | Using this technique, the incidence of acute GVHD was reduced to 20 percent (from 50 percent when unpurged bone marrow marrow is used), and the high rate of relapse experienced among leukemic patients who receive marrow completely purged of all T-cells did not occur. | | | Most patients with chronic GVHD experience skin problems that may include a dry itching rash, a change in skin color, and tautness or tightening of the skin. |
|
http://www.bmtinfonet.org/bmt/bmt.book/chapter.9.html
(2841 words)
|
|
| |
| | eMedicine - Graft Versus Host Disease : Article by Romeo A Mandanas, MD, FACP |
| | Fibrosis of the submucosa and serosa is observed in gastrointestinal involvement with chronic GVHD. | | | This boy developed stage 3 skin involvement with acute graft versus host disease (GVHD) in spite of receiving prophylaxis with cyclosporin A. The donor was an HLA-matched sister; the gender disparity increased the risk for acute GVHD (see Image 5). | | | PUVA therapy plays a role in patients with refractory cutaneous chronic GVHD, showing a 78% response rate in one study and some improvement in a few extracutaneous sites. |
|
http://www.emedicine.com/med/topic926.htm
(6789 words)
|
|
| |
| | Graft versus host disease porphylaxix |
| | In T-cell depletion of bone marrow however, the apparent advantage of reduced GVHD is offset by an increased incidence of graft rejection and disease relapse. | | | This approach is experimental and additional GVHD prophylaxis may not be required. | | | In comparative studies of FK506 + MTX versus CSA + MTX, the former has been shown to reduce the overall incidence of GvHD though incidence of severe (Grade III-IV) GvHD and overall survival was not affected. |
|
http://www.ngt.org.uk/bmt/GVHDproph.htm
(1887 words)
|
|
| |
| | Graft-Versus-Host Disease (GVHD) |
| | Because researchers are working to find better ways to treat GVHD, some treatments your doctors may offer may be available through clinical trials. | | | For both acute and chronic GVHD, the main treatment is to give steroids that weaken the immune system. | | | GVHD can affect many different parts of the body. |
|
http://www.marrow.org/PATIENT/gvhd.html
(1406 words)
|
|
| |
| | IBMT: FAQ - Graft-Versus-Host Disease |
| | Several drugs and procedures may be used to try and prevent acute GvHD. | | | The hardened skin and limited flexibility of joints are difficult to treat, sine they involve scarring of the skin. | | | This system, that originated at the Fred Hutchinson Cancer Center in Seattle, looks at involvement of skin, gut, and liver. |
|
http://www.ibmtindy.com/faq/graft.htm
(1667 words)
|
|
| |
| | TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE |
| | Survey of transfusion associated graft-versus-host disease in immunoco-mpetent recipients. | | | In Mintz P (ed): Transfusion Therapy: Clinical Principles and Practice. | | | It is seen in immunocompromised patients and pre-mature neonates. |
|
http://www.ayubmed.edu.pk/JAMC/PAST/15-3/masood.htm
(1897 words)
|
|
| |
| | ScienceDaily: Drugs Limit Deadly Side Effects Of Graft-versus-host Disease |
| | "We are very excited about what this kind of therapy could mean to patients with blood- and marrow-related cancers who need a transplant, but have a high risk of developing graft-versus-host disease," Ferrara says. | | | But this will need to be determined in well-designed clinical studies." | | | GVL represents the most potent known form of immune therapy against malignant diseases. |
|
http://www.sciencedaily.com/releases/2004/02/040229231914.htm
(1921 words)
|
|
| |
| | Control of graft versus host disease |
| | However, a life-threatening complication of this effective therapy is the development of graft versus host disease (GVHD) whereby the effector cells in the bone marrow attack various cells and structures of the recipient (host) of the bone marrow. | | | These cells survived in patients up to 12 months and in 5/12 patients exhibited anti-tumor activity. | | | Such strategy is likely to increase the effectiveness and safety of the bone marrow transplant in patients who require allogeneic bone marrow transplant. |
|
http://www.bioscience.org/news/scientis/gvhd1.htm
(340 words)
|
|
| |
| | Small Bowel - Graft versus Host Disease |
| | The morphological features of intestinal GVHD and acute rejection share a great degree of similarity. | | | GVHD occurred in most of the small bowel allograft recipients is usually not fatal by itself because of the heavy immunosuppressive therapy, though opportunistic infections secondary to the heavy immunosuppression are the frequent cause of death in these patients. | | | GVHD occurs in approximately 5% of patients receiving small bowel transplantation(1-2), which is approximately 5-10 times higher than in other solid organ transplantatiion. |
|
http://tpis.upmc.edu/tpis/smbowel/SGVHDa.html
(398 words)
|
|
| |
| | Graft versus Host Disease |
| | Symptoms may include skin rash, intestinal problems similar to colitis, and liver dysfunction. | | | This disease entry is based upon medical information available through the date at the end of the topic. | | | Graft versus Host Disease (GVHD) is a rare disorder that can strike persons whose immune system is suppressed and have either received a blood transfusion or a bone marrow transplant. |
|
http://www.peacehealth.org/kbase/nord/nord840.htm
(346 words)
|
|
| |
| | Graft-vs-Host Disease |
| | Alternative therapies are considered for patients whose GvHD does not respond to steroids. | | | Symptoms vary more widely than those of acute GvHD and are similar to various autoimmune disorders. | | | The incidence of GvHD increases with increasing degree of mismatch between donor and recipient HLA antigens, increasing donor age and increasing patient age. |
|
http://www.stjude.org/stem-cell-trans/0,2527,419_4124_6031,00.html
(415 words)
|
|
| |
| | Regulatory T cells keep graft-versus-host disease in check |
| | Bone marrow transplantation offers the hope of a complete cure for patients suffering from certain forms of cancer, such as leukemia or other immune deficiency diseases. | | | However, there is a risk that transplanted cells may recognize the recipient patient's tissues as foreign and begin to attack them. | | | The challenge however has been to obtain enough freshly purified CD4+CD25+ regulatory T cells from a single donor patient to achieve this therapeutic effect in a clinical setting. |
|
http://www.eurekalert.org/pub_releases/2003-12/joci-rtc112503.php
(290 words)
|
|
| |
| | graft versus host disease |
| | caused by immunologically competent T cells in the graft recognizing and attacking host tissues as foreign; clinical symptoms include skin rashes, diarrhea, and abnormal liver functions. |
|
http://crisp.cit.nih.gov/Thesaurus/00003445.htm
(26 words)
|
|
|
